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Abstract
The aggregation of proteins or peptides in amyloid fibrils is associated with a number of clinical disorders, including
Alzheimer’s, Huntington’s and prion diseases, medullary thyroid cancer, renal and cardiac amyloidosis. Despite extensive
studies, the molecular mechanisms underlying the initiation of fibril formation remain largely unknown. Several lines of
evidence revealed that short amino-acid segments (hot spots), located in amyloid precursor proteins act as seeds for fibril
elongation. Therefore, hot spots are potential targets for diagnostic/therapeutic applications, and a current challenge in
bioinformatics is the development of methods to accurately predict hot spots from protein sequences. In this paper, we
combined existing methods into a meta-predictor for hot spots prediction, called MetAmyl for METapredictor for AMYLoid
proteins. MetAmyl is based on a logistic regression model that aims at weighting predictions from a set of popular
algorithms, statistically selected as being the most informative and complementary predictors. We evaluated the
performances of MetAmyl through a large scale comparative study based on three independent datasets and thus
demonstrated its ability to differentiate between amyloidogenic and non-amyloidogenic polypeptides. Compared to 9
other methods, MetAmyl provides significant improvement in prediction on studied datasets. We further show that
MetAmyl is efficient to highlight the effect of point mutations involved in human amyloidosis, so we suggest this program
should be a useful complementary tool for the diagnosis of these diseases.
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Introduction
Amyloid fibrils are protein aggregates that are insoluble and
resistant to protease activity in vivo [1]. The formation and the
accumulation of amyloid aggregates, as implicated in the cellular
death process, are common features of a variety of neurodegen-
erative diseases such as Parkinson’s, Alzheimer’s, and Hunting-
ton’s diseases [2,3]. Extensive researches have shown a large
number of biological mechanisms involved in amyloidogenesis.
Mutations, maturation, protein synthesis errors, inappropriate
proteolysis and protein environment modification might lead to
the formation of amyloid fibrils [4]. Because of the complexity of
amyloidogenesis, predicting the capacity for a given protein to
form amyloid fibrils remains as of today a very challenging task.
A lot of studies has tried to understand the biological
mechanisms implicated in amyloidosis. Thus, all amyloid fibrils
are characterized by protein misfolding responsible for a common
cross-b architecture [5,6]. Moreover, recent studies highlighted the
fact that amyloid formation is mainly a sequence-specific process
[7–9] although proteins able to form amyloid-like fibrils share very
little similarity in native three-dimensional structure [3,10].
Theoretical and experimental evidence further indicate that short
peptidic sequences, often called ‘‘hot spots’’, play a major role in
amyloidogenesis [7,8,11]. Hot spots can form a complementary
interface with an identical segment and allow the formation of a
steric zipper made by two b sheets that form the spine of an
amyloid fibril. As the global structure of proteins is likely to
modulate amyloid propensity, the length of hot spot segments
might vary considerably. However, it has been experimental
demonstrated that the length of six residues, corresponding to
hexapeptides, is essential and sufficient for a segment to induce
amyloid conversion of an entire protein domain [12,13].
Understanding the role of short sequences in amyloid fibrilation
is so crucial that the past few years have seen the development of a
large number of methods dedicated to the prediction of amyloid
hot spots in proteins. In 2011, Hamodrakas proposed an overview
of the predictive methods and their related software published
since 2004 [14]. The author provided a short description of
different algorithms as for example: SALSA [15], 3D profile
[16,17], Pre-Amyl [18], PASTA [19], AGGRESCAN [20,21],
Zyggregator [22], TANGO [23], AMYLPRED [24], PAFIG [25],
Net-CSSP [26], BETASCAN [27], FoldAmyloid [28], Waltz [29].
Other methods have been developed, taking into account
additional features, such as amyloid fibril structural conformations,
and the effect of sequence mutations [30–33]. At this point it
should be noted that TANGO was not developed to detect
amyloidogenic regions, but rather b-sheet aggregates that are
considered as key intermediates on path to ordered fiber assembly
[34,35].
The large number of predictive methods reflects the complexity
of the biological mechanisms involved in amyloidosis. It is very
likely that the formation of amyloid fibrils is an intricate
phenomenon in which many features interplay (secondary
structures formation, disorder propensity, hydrophobicity, struc-
tural modeling energy, physico-chemical properties, amino-acid
context). However, existing predictors individually account for a
very few number of features, thus reducing the overall predicitive
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capacity of each method. The idea of associating different
predictors to increase the detection power was first introduced in
AMYLPRED [24], recently followed by the new version
AMYLPRED2 [36]. AMYLPRED2 accounts for the diversity of
11 individual predictors by the use of a consensus. Nevertheless,
the method faces a main limitation concerning the weighting
process for the combined predictors that impact the accuracy of
the approach. The consensus is based on binary predictions while
using the prediction scores as input in a meta-prediction might
increase the accuracy of the prediction.
In this paper, we propose a novel method based on a statistical
approach that efficiently combines well-known existing methods
into a meta-predictor in order to improve hot spot prediction. The
goal of our meta-predictor, called MetAmyl for METa-predictor
for AMYLoid proteins, is to exploit each individual predictor to
account for a large number of features known to play a role in
amyloidogenesis. The proposed approach is built on a statistical
framework that aims at selecting and combining individual
predictors by computing a weighted combination of predictor
scores. The design of the linear combination is achieved through a
logistic regression model that weights the input scores to provide
the best estimate of the probability of a peptide to be an
amyloidogenic segment. The estimation of our logistic model is
performed on a publicy available training dataset [16,29] and is
decomposed into two main steps. In a first step, we automatically
select the most informative and complementary set of individual
predictors among the existing methods in the literature. The four
selected predictors were SALSA, PAFIG, FoldAmyloid and Waltz.
In our case, in a second step, weights are statistically assigned to
each of the selected scores by maximizing a likelihood function.
The evaluation of MetAmyl is composed of two parts. In a first
part, the training dataset is used to evaluate MetAmyl accuracy
with respect to well-known predictors by estimating their capacity
to correctly detect amyloid-forming hexapeptides as well as non-
amyloid-forming hexapeptides. For this evaluation, cross-valida-
tion has been performed on the training dataset to accurately
estimate the performances of MetAmyl. In a second part, we used
two recently published dataset, one composed of 33 proteins from
the amylome and the other made by randomly shuffle sequences
from the the N-terminus of the Huntington’s disease protein
huntingtin, to investigate the predictive capacity of each compared
predictor on experimentally-validated regions [36]. Comparative
analyses show that MetAmyl improves predictions on the three
datasets. Moreover, to illustrate the benefit of a prediction score
instead of a binary prediction as proposed by other metapredic-
tors, we evaluate MetAmyl prediction of the effect of mutations in
human fibrinogen-a. Our study points out the ability for MetAmyl
to quantitatively predict the effect of mutations involved in renal
amyloidosis.
Materials and Methods
In this section, the statistical framework used to build MetAmyl
score as a combination of individual predictor scores is first
described. Then, MetAmyl computation together with the
companion online application are presented. Finally, the three
independent datasets used to train and validate MetAmyl are
described as well as the comparative analysis of MetAmyl against 9
other predictors.
MetAmyl score
MetAmyl is based on a logistic regression model that aims at
weighting the different input scores to provide the most relevant
combination of individual predictors. In this study, we used eleven
input scores in the logistic framework. These eleven scores
correspond to eleven recently published predictive algorithms:
PASTA, SALSA, AGGRESCAN, PAFIG, FoldAmyloid (5 tables),
TANGO and Waltz. These eleven predictors were chosen as
proposing either an executable code or a sufficiently detailed
algorithm to be implemented. The design of our model relies on
the training dataset and is composed of two main steps, both
performed using the statistical software R [37,38]. First, we
automatically select the set of individual predictors using stepwise
variable selection algorithm [39–42]. This first step is common in
supervised classification as variable selection generally alleviates
the effect of the curse of dimensionality, enhances generalization
by reducing overfitting and also improves model interpretabili-
ty[38,42]. In our case, training the complete model, made by the
11 individual predictors, requires the estimation of 12 coefficients.
With respect to the size of the training dataset (278 sequences),
training of the complete model lacks in accuracy due to high
variability in coefficient estimation. As a result, four individual
predictors are statistically selected in MetAmyl as being the most
informative and complementary set of individual prediction scores:
SALSA, PAFIG, Waltz and the first table from FoldAmyloid. One
can remark that the 7 other scores were removed as being
correlated with the selected individual predictors. Indeed, the five
tables from FoldAmyloid are highly correlated; PASTA and
SALSA showed very strong correlation; TANGO was very closed
to Waltz and AGGRESCAN was correlated with FoldAmyloid.
Thus, MetAmyl is given by the following regression model:
log
p(x)
1{p(x)
 
~b0zb1SPAFIG(x)zb2SSALSA(x)
zb3SWaltz(x)zb4SFA1(x)
ð1Þ
where p(x) is the probability that the hexapeptide x is an ‘‘hot
spot’’. SPAFIG(x), SSALSA(x), SWaltz(x) and SFA(x) are the
amyloidogenic scores for x obtained with the four individual
predictors PAFIG, SALSA, Waltz and the first table from
FoldAmyloid. In a second step, the estimation of the regression
coefficients is achieved by maximizing the likelihood of the
obtained logistic model. Details of the variable selection procedure
are given in Text S1 (see paragraph Stepwise variable selection in
section Supplementary Methods and Table S1). Furthermore,
values of the estimated b coefficients are reported in the paragraph
MetAmyl Score in Text S1. The interpretation of these
coefficients, that act as weights to each individual predictor,
reveals that PAFIG, SALSA, Waltz and FA1 provide equivalent
contribution to MetAmyl score (see paragraph Interpretation of
the coefficients in section Supplementary Methods).
Implementation, profile calculation and hot spot
prediction
MetAmyl is available online at the following url: http://
metamyl.genouest.org/. For an input amino-acid sequence, an
amyloidogenic profile is computed by the use of a sliding window
with a fix number of 6 amino acids. The score for each
hexapeptide is obtained by applying MetAmyl score as described
in Equation 1. The computation of the complete profile is
performed by assigning the score of each hexapeptide to its third
residue.
MetAmyl has been designed to manipulate large scale datasets.
We first computed the 64,000,000 hexapeptides scores corre-
sponding to the combinatorial diversity of amino-acids and we
stored them on the server. Thus, the building of the profile of an
input sequence consists in uploading MetAmyl scores from the
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server instead of calculating it for each window, which accelerates
the computation of the MetAmyl profile.
If the MetAmyl score of an hexapeptide is above the best global
accuracy threshold, the hexapeptide is predicted as amyloid-
forming. The best global accuracy threshold is statistically
obtained by maximizing a function of the sensitivity and the
specificity of our meta-predictor on the training dataset. More
precisely, we focused on maximizing the distance to the upper-left
corner in the ROC curve, which corresponds to the cut-off that
maximises the quantity (1{sensitivity)2z(1{specificity)2 [43].
In our analysis, we obtained the same optimal cut-off by using
Youden’s J statistic that aims at maximizing
SpecificityzSensitivity{1 [44]. A high specificity threshold
and a high sensitivity threshold are also proposed as alternatives
on the MetAmyl Website, allowing users to analyze their results in
different conditions. To prevent from overfitting, we used a Leave-
One-Out cross-validation to estimate MetAmyl thresholds.
A ‘‘hot spot’’ is then defined as a contiguous serie of
amyloidogenic hexapeptides. The use of a sliding window allows
the detection of variable length hot spots. In order to quantify the
amyloidogenicity propensity of a hot spot, the Total Area (TA) and
the Normalized Hot Spot Area (NHSA) are calculated following
the method used in AGGRESCAN [21]. TA is defined as the sum
of scores of hexapeptides along the entire input sequence and
NHSA is the area between the threshold and the profile divided by
the length of the predicted segment.
Datasets
The predictive performances of MetAmyl were compared to
existing methods using the three independent datasets called
respectively training dataset, amylome subset and httNT.
The training dataset is a compilation of the Amylhex and
Waltz databases designed by [29] and contains 278 hexapeptides
for which experiments have been performed to determine their
capacity to form amyloid aggregates. It is composed of 116
amyloid-forming hexapeptides (positive set) and 162 non-amyloid-
forming hexapeptides (negative set). In our study, the training
dataset was first used to estimate MetAmyl score and next to
evaluate the capacity of MetAmyl to predict the amyloid status of
hexapeptides.
The second dataset, called amylome subset, is composed of
33 proteins from the amylome and has been recently used to
evaluate AMYLPRED2 predictions [36]. The amylome subset
is a collection of proteins for which experimental data validated 70
hot spots. Details regarding the dataset and the references that
support hot spots validation can be found in Table S1 of [36].
Assessing the accuracy of hot spots prediction methods is a difficult
task because there is only a relatively small number of
experimentally confirmed amyloid regions (true positive, TP),
and even less for confirmed non-amyloid regions (true negative,
TN). Another essential element involved in the difficulty to classify
peptides in a positive or negative group is linked to the
polymorphism of amyloid fibrils, which may depend on the
experimental conditions used [45–47]. These are reasons why we
chose the valuation dataset proposed by Tsolis et al., enabling a fair
comparison between AMYLPRED2 and MetAmyl which both
propose consensus-based methods to predict aggregation prone
regions.
In complement to the amylome subset we used a third dataset,
called httNT, recently published by Roland and collaborators [48].
It is composed of peptides generated from the human Huntingtin
protein. Using the 18 amino acids of the N terminus of the wild
type protein the authors synthesized 15 scrambled sequences
(peptides with the same amino acids but in a different order) whose
aggregative properties were studied in vitro in simulated physio-
logical conditions. As summarized in Table S6, 3 peptides grow
rapidly into amyloid fibrils, 2 peptides aggregate more slowly and
one aggregates only at high concentrations. It results that our third
dataset is composed of 6 amyloid peptides and 10 non-amyloid
peptides.
Comparative analysis
Based on the training dataset, we first compared the overall
performances of each predictor by the use of Receiver Operating
Characteristic (ROC curves). ROC curves estimation is based on
sensitivity and specificity that are estimated at different thresholds
applied to the output score. Thus, ROC curve computation is not
feasible for AMYLPRED2 as its prediction is binary. We further
investigated the classification performances of each predictor
based on confusion matrices obtained by applying provided hot
spot thresholds to each score using the training dataset. Confusion
matrices are summarized by four classical indicators: accuracy
measured as ACC~(TNzTP)=(TNzTPzFNzFP), sensiti-
vity asTP=(TPzFN), specificity asTN=(TNzFP) andMatthews
Correlation Coefficient as MCC~(TP  TN{FP  FN)=ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(TNzFN)|(TNzFP)|(TPzFN)|(TPzFP)
p
, where TP
(resp. TN, FP, and FN) is the number of True Positives (resp. True
Negatives, False Positives and False Negatives). For the following
individual predictors, 3D profile, AGGRESCAN, FoldAmyloid,
PAFIG, PASTA, SALSA and TANGO, we used defined thresholds
as proposed by the authors. For Waltz, the best overall performance
threshold was used. Regarding our meta-predictor, MetAmyl, we
used a Leave-One-Out Cross Validation of the classification results
in order to avoid overfitting. To allow a better interpretation of the
observed differences between compared methods, confidence
intervals for all indicators have been computed using bootstrap
replicates [43,49,50].
We tested MetAmyl against the following individual predictors
3D profile, AGGRESCAN, FoldAmyloid, PAFIG, PASTA,
SALSA, TANGO and Waltz on the amylome subset. We also
compared MetAmyl performances against the metapredictor
AMYLPRED2. By screening the 33 proteins of the amylome
subset, we counted, for each predictor, the number of true
positives (TP), true negatives (TN), false positives (FP) and false
negatives (FN ) on a per residue basis, as suggested by [36]. To
summarize predictor classification, we further computed the
following values: sensitivity, specificity, Matthews Correlation
Coefficient, Q value measured as (sensitivity+specificity)/2 and
F1 score as 2TP=(2TPzFPzFN). A similar comparative
analysis has been conducted on the httNT dataset.
Results
MetAmyl aims at accounting for most biological features
implicated in the amyloidogenesis by combining the asset of
existing predictors. To evaluate the benefit of our approach we
compared the performances of MetAmyl against 9 predictors on
three independent datasets.
Comparative analysis on the training dataset
The aim of our analysis of the training dataset was to evaluate
and to compare the global accuracy of MetAmyl against existing
predictors. At first, predictor performances were assessed by the
use of ROC curves. Then, confusion matrices for each predictor
were investigated in order to group predictive methods with
respect to their statistical patterns.
Figure 1 displays the ROC curves for MetAmyl, obtained with
Leave-One-Out cross-validation, and the four selected predictors:
MetAmyl: A METa-Predictor for AMYLoid Proteins
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FoldAmyloid, PAFIG, SALSA and Waltz. One can see that
MetAmyl outperformed the individual predictors. MetAmyl ROC
curve is indeed above the other curves except in case of very high
sensitivity. Similar conclusions are obtained when comparing the
ROC curves for all compared predictors (see Figure S1). This
result is confirmed by the comparison of the AUC (Area Under the
Curve) for the different predictors. Results reported in Table 1
show that MetAmyl has the highest AUC (0.89) which is
significantly higher than the other methods, according to De-
Long’s test (DeLong, 1988). Significance was also assessed using
bootstrap replicates that allow for the estimation of 95%
confidence intervals (Fawcett, 2006 and Robin, 2011) demon-
strating that none of the AUC fell into MetAmyl AUC confidence
interval. Furthermore, in order to perform a more useful
comparison, we limited the calculation of the AUC for False
Positive Rate in (FPR: 0–20%) and in (FPR: 0–5%). Results
displayed in Table 1 revealed that MetAmyl has a significantly
higher AUC than all other methods in case of low False Positive
Rate.
Comparative analysis of the confusion matrices obtained for
each predictor is summarized in Table 2. Accuracy, sensitivity,
specificity and the Matthews Correlation Coefficient (MCC) are
reported for the 10 compared predictors. 95% confidence
intervals, obtained using bootstrap replicates [43,50] are also
reported. Based on results presented in Table 2, predictors are
clustered in four groups according to their statistical patterns. In a
first group, predictors MetAmyl and Waltz showed reasonable
accuracy characterized by high sensitivity and high specificity. The
second group is composed of 4 predictors (PAFIG, SALSA,
AGGRESCAN, FoldAmyloid) having good sensitivity but poor
specificity. On the contrary, the third group includes 3 predictors
(PASTA, TANGO, AMYLPRED2) sharing an acceptable spec-
ificity and a low sensitivity. Finally the fourth group characterizes
3D profile that showed lack both in sensitivity and specificity.
In terms of accuracy, MetAmyl outperformed the other
methods with a correct classification rate of 0:84. Predictors
Waltz and AMYLPRED2 gave acceptable results with accuracies
of 0:79. However, according to confidence intervals, Waltz and
AMYLPRED2 accuracies are significantly lower than MetAmyl
accuracy (see Table 2). All other methods showed poor global
performances with a correct classification rate lower than 0:75.
These results are enhanced by the fact that MetAmyl MCC is
significantly higher than the compared predictors.
In more details, the predictors from the second group (PAFIG,
SALSA, AGGRESCAN and FoldAmyloid) are able to detect
amyloid hexapeptides (sensitivity higher than 0:80). However these
four predictors showed a tendency to also detect false positives
with specificities lower than 0:6. For AGGRESCAN and
FoldAmyloid, the true negative rate is even lower than 0:50
meaning that more than half of the non-amyloid hexapeptides is
misclassified. AMYLPRED2, PASTA and TANGO provided an
opposite statistical pattern. These three predictors have indeed a
very good capacity at predicting non-amyloid hexapeptides, with
Figure 1. Receiver operating characteristic (ROC curves)
obtained for the 4 selected predictors, PAFIG, SALSA, Fold
Amyloid and Waltz, and Leave-One-Out cross validated
MetAmyl on the training dataset.
doi:10.1371/journal.pone.0079722.g001
Table 1. Area Under the Curve (AUC) based on the training dataset.
Predictor AUC [95% CI] p.value AUC [95% CI] AUC [95% CI]
(AUC vs MetAmyl AUC) (FPR: 0–20%) (FPR: 0–5%)
MetAmyl 0.89 [0.87–0.92] 1 0.13 [0.12–0.15] 0.018 [0.014–0.024]
Waltz 0.85 [0.82–0.88] 0.029 0.10 [0.07–0.11] 0.005 [0.002–0.011]
PAFIG 0.82 [0.79–0.86] 0.016 0.10 [0.08–0.11] 0.011 [0.008–0.016]
PASTA 0.80 [0.77–0.84] 6.7|10{6 0.08 [0.07–0.10] 0.005 [0.002–0.010]
SALSA 0.79 [0.76–0.83] 8.8|10{7 0.08 [0.06–0.09] 0.007 [0.005–0.010]
AGGRESCAN 0.76 [0.72–0.80] 2.1|10{8 0.07 [0.05–0.08] 0.003 [0.001–0.006]
3D profile 0.75 [0.72–0.79] 1.9|10{9 0.07 [0.06–0.09] 0.008 [0.005–0.011]
FoldAmyloid 0.69 [0.65–0.73] 1.7|10{11 0.04 [0.03–0.05] 0.001 [0.000–0.003]
TANGO 0.67 [0.64–0.71] 2.1|10{14 0.05 [0.03–0.06] 0.003 [0.001–0.006]
Area Under the Curve (AUC) was obtained from the ROC curves of 9 predictors: AUC cannot be computed for AMYLPRED2 as it provides only a binary prediction. For
each method, the global AUC, the AUC for the False Positive Rate range of 0–20% and the AUC for the False Positive Rate range of 0–5% are reported. Numbers in
brackets correspond to 95% confidence intervals (95% C.I.) that were obtained using bootstrap replicates [43]. The comparison of MetAmyl AUC and the other methods
is summarized by the p.value obtained with Delong’s method [49]. For the MetAmyl classifier, results were obtained using a Leave-One-Out Cross Validation.
doi:10.1371/journal.pone.0079722.t001
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specificities higher than 0:80. The counterpart is their poor
sensitivity of their predictions.
On the training dataset, our results demonstrate that using a
weighted combination of predictors increases the prediction
accuracy of hexapeptides. MetAmyl accuracy is not over estimated
by effect of overfitting as results presented in Tables 1 and 2 used a
Leave-One-Out cross-validation. Effect of cross-validation on
MetAmyl performances is displayed in Table S2 that reports the
global measures (AUC, ACC and MCC) in four situations: no
cross-validation, Leave-One-Out cross-validation, 10-fold cross-
validation and 20-fold cross-validation. Results without cross-validation
are artificially improved compared to performances in the three
cross-validation set-ups that are equivalent.
Investigation of a subset of proteins from the amylome
In a second study, we compared MetAmyl prediction with 9
predictors by estimating the ability of each method to detect hot
spots in a set of 33 proteins belonging to the amylome [36]. Our
results show that MetAmyl has the best Q value, MCC and F1
score compared to the other predictors (see Table 3 and Table S5
for the detail of MetAmyl hotspot prediction). Regarding Q values,
MetAmyl (62:27%) is followed by PAFIG (61:59%),
AMYLPRED2 (61:02%) and Waltz (60:93%). Furthermore,
MetAmyl has the highest MCC (0:23) while the second and third
best MCC are AMYLPRED2 (0:20) and PAFIG (0:18). Concern-
ing F1 score, MetAmyl (0:36) is followed by PAFIG (0:34),
AMYLPRED2 (0:34%) and Waltz (0:33%). Using bootstrap
replicates, we computed 95% confidence intervals and results
reported in Table S3 show that MetAmyl has a significantly higher
MCC and F1 score than the other methods. Moreover, MetAmyl
has a significantly higher Q value than all other predictors except
PAFIG.
MetAmyl performances on the amylome subset are confirmed
by the comparison of the area under the ROC curves displayed in
Figure S2. Numerical results reported in Table S4 shows that
MetAmyl has the highest AUC (0.67) followed by PAFIG
(AUC=0.62), SALSA (AUC=0.61) and PASTA (AUC=0.61).
Furthermore, according to DeLong’s test [49], MetAmyl AUC is
significantly higher than AUC for the other methods: pvalue
obtained with the comparison with the second best method,
PAFIG, is equal to 4:3|10{7. As pointed out in [36], upcoming
experimental data may generate changes in results and numbers
reported in Tables 3, S3 and S4, as well as Figure S2.
Table 2. Prediction performances, based on the training dataset are given for the 10 compared predictors.
Predictor ACC [95% CI] Sensitivity [95% CI] Specificity [95% CI] MCC [95% CI]
MetAmyl 0.84 [0.81–0.87] 0.78 [0.73–0.82] 0.88 [0.85–0.92] 0.67 [0.60–0.72]
Waltz 0.79 [0.76–0.82] 0.73 [0.68–0.77] 0.83 [0.79–0.88] 0.57 [0.50–0.63]
PAFIG 0.69 [0.65–0.72] 0.84 [0.80–0.89] 0.57 [0.53–0.63] 0.42 [0.36–0.49]
PASTA 0.71 [0.67–0.74] 0.38 [0.32–0.44] 0.94 [0.92–0.97] 0.41 [0.34–0.47]
SALSA 0.69 [0.66–0.73] 0.84 [0.80–0.89] 0.59 [0.54–0.64] 0.43 [0.37–0.50]
AGGRESCAN 0.55 [0.51–0.59] 0.92 [0.89–0.95] 0.29 [0.24–0.34] 0.26 [0.20–0.32]
3D profile 0.66 [0.63–0.70] 0.59 [0.53–0.65] 0.71 [0.67–0.75] 0.31 [0.23–0.37]
FoldAmyloid 0.61 [0.58–0.65] 0.87 [0.83–0.91] 0.43 [0.38–0.48] 0.32 [0.26–0.39]
TANGO 0.69 [0.66–0.73] 0.52 [0.46–0.58] 0.82 [0.78–0.86] 0.36 [0.29–0.43]
AMYLPRED22 0.79 [0.76–0.82] 0.65 [0.60–0.71] 0.88 [0.85–0.92] 0.57 [0.50–0.63]
For each method, the accuracy, the sensitivity, the specificity and the Matthews correlation coefficients (MCC) are reported. Numbers in brackets correspond to 95%
confidence intervals (95% C.I.) that were obtained using bootstrap replicates (Robin et al., 2011). For the MetAmyl classifier, results were obtained using a Leave-One-
Out Cross Validation.
doi:10.1371/journal.pone.0079722.t002
Table 3. Evaluation of the performance of the tool MetAmyl on a subset of 33 proteins of the amylome.
Predictor TP TN FP FN Sensitivity (%) Specificity (%) Q (%) MCC F1
MetAmyl 508 5519 1064 740 40.71 83.84 62.27 0.23 0.36
Waltz 710 4300 2273 548 56.43 65.42 60.93 0.16 0.33
PAFIG 651 4695 1878 607 51.75 71.43 61.59 0.18 0.34
PASTA 230 6099 484 1018 18.43 92.65 55.54 0.14 0.23
SALSA 869 3123 3460 379 69.63 47.44 58.54 0.13 0.31
AGGRESCAN 445 5210 1363 813 35.37 79.26 57.32 0.13 0.29
3D profile 224 5762 821 1024 17.95 87.53 52.74 0.06 0.20
FoldAmyloid 340 5659 924 908 27.24 85.96 56.60 0.13 0.27
TANGO 172 6282 291 1086 13.67 95.57 54.62 0.14 0.20
AMYLPRED2 478 5512 1071 770 38.30 83.73 61.02 0.20 0.34
MetAmyl is compared to 9 other methods on a subset of 33 proteins (Tsolis et al., 2013).
doi:10.1371/journal.pone.0079722.t003
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The study of the amylome subset shows that the four individual
predictors including in MetAmyl, namely PAFIG, SALSA, Waltz
and FolAmyloid, exhibit different statistical patterns. On one
hand, PAFIG and Waltz are both specific with a reasonable
sensitivity. On the other hand, SALSA is highly sensitive with a
poor specificity and finally, FoldAmyloid has a very high specificity
balanced by a very low sensitivity. Thus, MetAmyl performance
on the amylome subset (independent of the training dataset)
establishes that MetAmyl efficiently combines these four predictors
according to their complementary statistical patterns. MetAmyl
benefits from the sensibility of SALSA while accounting for the
FoldAmyloid, PAFIG and Waltz specificities, allowing for a better
control of the false positive rate.
Investigation of scrambled sequences from httNT
Using a recently published dataset composed of scrambled
sequences from 17-amino acid peptide segment, we compared
MetAmyl predictive performances with 9 existing predictors [48].
Predictions are summarized by the three following statistical
quantities: Q value, MCC and F1 score (see Table 4). Further-
more, 95% confidence intervals have been computed using
bootstrap replicates (see Table S7). Our comparative analysis
shows that only 2 sequences over 16 are missclassified by MetAmyl
which makes MetAmyl the best predictor with respect to Q value,
MCC and F1 score (see Table 4). MetAmyl has indeed the best Q
value (83.33%) which is statistically higher than the other
predictors as for example AMYLPRED2 that have the second
highest Q value (75%). Furthermore, MetAmyl has statistically the
highest MCC (0.74) while the second and third best MCC are
AMYLPRED2 (0.52) and Waltz (0.48). Regarding F1 score,
MetAmyl reach the score of 0.8 and is followed by AMYLPRED2
(0.7) that falls into MetAmyl 95% confidence interval. The 8 other
predictors have a significantly lower F1 score.
Our results show that the 4 individual predictors used to built
MetAmyl score have complementary statistical patterns. On one
hand PAFIG and FoldAmyloid are highly sensitive with a very
poor specificity. On the other hand, Waltz combines high
specificity and low sensitivity. Finally SALSA proposes an
acceptable trade-off between specificity and sensitivity. Thus,
MetAmyl performance on the Huntingtin dataset proves that
MetAmyl efficiently combines these four predictors by using Waltz
and SALSA specificities and PAFIG, SALSA and FoldAmyloid
sensitivities.
Example of disease-associated variants
In this section, we assess the capacity for MetAmyl to predict the
effect of single mutations in human fibrinogen-a. Fibrinogen has
multiple biological functions and is a key protein of the
coagulation pathway. Mutations in this gene lead to several
disorders including hereditary renal/cardiac amyloidosis. The
amyloid fibrils found in patients with renal amyloidosis are
composed of fragments of fibrinogen encompassing residues 500 to
580 [51,52]. So, we performed a systematic literature analysis in
order to identify all known mutations affecting this region of the
protein and linked to renal amyloidosis [53–61]. Our analysis also
included screening of four databases: Ensembl [62], GEHT [63],
cBioPortal [64], and www.amyloidosismutations.com. We com-
piled thirteen mutations having two types of consequences on
fibrinogen: substitution of one amino-acid by another (missense
mutation), or insertion of some amino-acids not found in the
native sequence followed by premature termination of the protein
(frameshift mutation). Only three missense mutations cause no
detectable pathology, and are thus considered non-pathological
variants. As shown in Figure 2, MetAmyl predicts how changes in
the sequence of fibrinogen can affect its aggregation propensity.
Moreover, one can see that 9 out of 10 mutations associated with
renal amyloidosis show an increased of their DTA score.
Discussion
By using a weighted combination of selected individual scores,
MetAmyl has efficiently integrated predictors into a meta-
predictor. We demonstrated in this paper the benefits of
combining predictive algorithms based on a statistical framework.
In the context of a complex trait, such as amyloidogenesis,
merging existing predictors has allowed MetAmyl to account for a
broad scale of features in a single predictor.
The evaluation of MetAmyl on three independent datasets
revealed its accuracy to predict amyloidogenic segments in
polypeptide chains and/or proteins. On the training dataset,
MetAmyl has a significantly higher AUC, Accuracy and Matthews
correlation coefficient than the other predictors. Moreover, on the
amylome dataset, MetAmyl has the best Q value, Matthews
correlation coefficient and F1 score. The potential overfitting for
MetAmyl on the training dataset has been controlled by the use of
cross-validation which is enhanced by MetAmyl performance on
the amylome subset and the httNT dataset. Although it is based on
Table 4. Evaluation of the performance of the tool MetAmyl on scrambled sequences from the 17- amino acid N-terminal segment
of the Huntingtin protein.
Predictor TP TN FP FN Sensitivity (%) Specificity (%) Q (%) MCC F1
MetAmyl 4 10 0 2 66.67 100 83.33 0.75 0.8
Waltz 2 10 0 4 33.33 100 66.67 0.49 0.5
PAFIG 5 3 7 1 83.33 30 56.67 0.15 0.56
PASTA 5 2 8 1 83.33 20 51.67 0.04 0.53
SALSA 5 6 4 1 83.33 60 71.67 0.42 0.67
AGGRESCAN 6 1 9 0 100 10 55 0.2 0.57
3D profile 4 0 10 2 66.67 0 33.33 20.49 0.4
FoldAmyloid 6 1 9 0 100 10 55 0.2 0.57
Tango 2 7 3 4 33.33 70 51.67 0.03 0.36
AMYLPRED2 6 5 5 0 100 50 75 0.52 0.71
MetAmyl is compared to 9 other methods on a set of 16 amino acid segments obtained from the Huntingtin protein [48].
doi:10.1371/journal.pone.0079722.t004
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a large number of experimentally validated amyloid regions, the
amylome subset suffers from a lack of validated non-amyloid
regions, which can affect the results of performance calculations.
For this reason, we used a third test set, named httNT and
independent of the training dataset the amylome subset. The httNT
dataset has been chosen as being unbiased with regard to the
correct assignment of amyloid or non-amyloid. Furthermore, the
httNT dataset illustrates the fact that polypeptides whose order has
been randomly shuffled, can lead to various aggregation patterns
(see Table S6). In the result section above, we showed that
MetAmyl gives the best classification accuracy in comparison to 9
other predictors. Also, MetAmyl outperforms Zyggregator, soft-
ware tested by the authors of the httNT dataset [48,65]. MetAmyl
predicts a relevant hot spot of aggregation in four out of six
amyloid-forming peptides (SP8, SP13, SP14, SP15). Moreover,
none hot spot is predicted in the 10 non-amyloid peptides. The
100% specificity of MetAmyl on the httNT dataset is explained by
a contribution from Waltz. In addition, FoldAmyloid correctly
predicts the 6 amyloid-forming peptides, which greatly contributes
to increase lack of sensitivity of Waltz. Waltz uses a position-
specific scoring matrix for amyloid prediction, which, according to
their authors, allows the distinction between amyloid fibrils and
amorphous -sheet aggregates [29]. Perhaps it is a reason why
peptides SP10 and SP11 are not correctly predicted by MetAmyl.
Indeed, electron micrographs of scrambled sequences shown in
[48] are far from representing well-ordered fibrillar structures.
MetAmyl behavior can be explained by the fact that it efficiently
combines four complementary predictors: PAFIG, SALSA, Waltz
and FoldAmyloid. First, our results demonstrated SALSA ability to
detect amyloidogenic segments while being non-specific. SALSA
has indeed a tendency to inappropriately predict hot spots:
amyloidogenic prediction covers more than 56% of the studied
subset of the amylome. Next, PAFIG and FoldAmyloid shared a
very similar statistical pattern on both datasets. They are indeed
sensitive (w0:8) but not specific (v0:6) on the training dataset.
Furthermore, PAFIG and FoldAmyloid are specific on the
amylome subset (w70%) but lack in sensitivity especially
FoldAmyloid (v30%). Finally, the Waltz predictor is very specific
but lacks in sensitivity, which, in a sense, prevents MetAmyl from
being too sensitive. Thus, MetAmyl can be seen as a trade-off
between sensitive and specific methods leading to a significant
improvement of the overall accuracy.
Moreover, combining PAFIG, SALSA, Waltz and FoldAmyloid
allows MetAmyl to account for a large scale biological features
related to amylose. In fact, MetAmyl prediction integrates the
following features: the ability to form b-strands, the propensity to
form b-sheets [23,25], disorder prediction [28], hydrophobicity
[25,29], structural modeling energy [29], support vector machine
(SVM) exploited 41 physico-chemical properties [25] and a
position-specific matrix [29]. Our results confirm that all these
features play a role in amyloidogenesis.
In figure 2 we show a remarkable example concerning the
effects of disease-associated mutations on MetAmyl aggregation
profiles. According to the algorithm, an amino acid substitution
involves six contiguous hexapeptides, thus amplifying the change
in the MetAmyl score in a sequence-dependent manner. As shown
in the bar-graph, there is an increased DTA score in variants
linked to renal amyloidosis, except for R554L. However, this
variant was reported to be associated with dilated cardiomyopathy
rather than restrictive cardiomyopathy typical of hereditary
amyloidosis [58]. Two other variants at the same position in the
sequence have been identified in patients with thrombosis
[56,59,66–68]. The R554C variant has no renal deposits but
shows an increase in the ability to self-associate
(DTAscore~z30). The clinical phenotype of the R554H variant
is a thromboembolic pulmonary hypertension without renal
amyloidosis (DATscore~0). Although prediction of a clinical
phenotype is not yet possible by bioinformatics methods, the
observations done on fibrinogen suggest that MetAmyl can help to
predict the effects of mutations on aggregation propensity of
proteins. It should also be noted that such analysis cannot be
performed by a predictor without a score of prediction such as
AMYLPRED2 for example. The use of a quantitative score for
MetAmyl allows for investigating the effect of variants.
Moreover, MetAmyl, available at http://metamyl.genouest.
org/, allows for large-scale analysis of polypeptidic segments and/
or proteins. The screening, with MetAmyl, of dedicated amyloid
protein databases might help to better understand the formation of
amyloid fibrils [67,70]. Thus, the propensity of some proteins to
convert into their amyloid state might be investigated and
MetAmyl could give new insights in explaining the development
of neurodegenerative diseases.
Conclusion
Accurate prediction of amyloid aggregation from the analysis of
the primary sequence of proteins is a long and difficult way. In this
paper we show that a statistical combination of several algorithms
improves the reliability of individual methods. We sincerely thank
all colleagues in the field who, in developing these methods have
allowed the realization of an efficient meta-predictor. Generally,
the predictors are tested on their ability to find amyloid-forming
regions defined on the basis of in vitro experiments. However, it is
known that amyloid fibers are polymorphic and their structural
properties depend on many parameters [71]. Therefore, accurate
prediction of amyloid-forming regions needs a large increase in
Figure 2. Metamyl predictions applied to human fibrinogen-a.
The effect of mutations is reported on a diagram where each column
represents the difference of TA scores between the mutant and the
corresponding wild-type sequence. The analysis is limited to mutations
affecting the fragment of 80 amino acids found in amyloid fibrils, which
is the region 500–580 of the mature protein. In red are variants involved
in renal amyloidosis. In blue are non-pathological variants.
doi:10.1371/journal.pone.0079722.g002
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properly validated benchmark datasets, without noise regarding
classification in amyloid fibrils and amorphous b-aggregates.
Supporting Information
Figure S1 Receiver Operating Characteristic (ROC curves).
ROC obtained for the 9 compared predictors on the training
dataset. Predictor AMYLPRED2 is not plotted because it proposes
a binary prediction which prevents the estimation of a ROC curve.
(TIFF)
Figure S2 Receiver Operating Characteristic (ROC curves).
ROC obtained for the 9 compared predictors on the amylome
subset. Predictor AMYLPRED2 is not plotted because it proposes
a binary prediction which prevents the estimation of a ROC curve.
(TIFF)
Table S1 Variable selection steps. Values reported are Bayesian
Information Criterion (BIC). * means that the variable is already
in the model and the stepwise procedure tries to exclude it.
(PDF)
Table S2 Cross-validation for MetAmyl in the training dataset.
Area under the curve (AUC), Accuracy (ACC) and Matthew’s
correlation coefficients (MCC) were computed for MetAmyl in
four situation: No cross-validation (No CV), Leave-One-Out
Cross-Validation (LOO), 10 Fold Cross-Validation (10Fold CV)
and 20 Fold Cross-Validation (20Fold CV). Numbers in brackets
correspond to 95% confidence intervals (95% C.I.) that were
obtained using 2000 bootstrap replicates (Robin et al., 2011).
(PDF)
Table S3 Prediction performances based on the amylome
dataset are given for the 10 compared predictors. For each
method, the accuracy, the sensitivity, the specificity and the
Matthews correlation coefficients (MCC) are reported. Numbers
in brackets correspond to 95% confidence intervals (95% C.I.) that
were obtained using bootstrap replicates (Robin et al., 2011).
(PDF)
Table S4 Area Under the Curve (AUC) based on the amylome
subset. Area Under the Curve (AUC) was obtained from the ROC
curves of 9 predictors: AUC cannot be computed for
AMYLPRED2 as it provides only a binary prediction. For each
method, the global AUC, the AUC for the False Positive Rate
range of 0–20% and the AUC for the False Positive Rate range of
0–5% are reported. Numbers in brackets correspond to 95%
confidence intervals (95% C.I.) that were obtained using bootstrap
replicates (Robin et al., 2011). The comparison of MetAmyl AUC
and the other method is summarized by the pvalue obtained with
Delong’s method (Delong et al., 1988).
(PDF)
Table S5 Prediction of amyloidogenic regions for MetAmyl on
the Amylome subset. The residue numbering for the sequence
features (second column) refers to the respective Uniprot entries.
The residue numbering for the experimental and predicted regions
(remaining columns) refers to the mature protein only. Sequences
of the mature proteins as well as relevant literature used to obtain
experimental information can be found in Table S1 of (Tsolis et al.,
2013).
(PDF)
Table S6 Descritption of the Huntingtin dataset. This table
summarizes the experiments made by Roland et al. (2013) where
amyloid forming properties have been studied for 16 sequences
(SP1-SP15 and HttNTQ). Additionnal comments have been added
for the sequences able to form amyloid fibrils. Furthermore,
MetAmyl hot spots prediction is given in the last column.
(PDF)
Table S7 Prediction performances based on the Huntingtin
dataset are given for the 10 compared predictors. For each
method, the accuracy, the sensitivity, the specificity and the
Matthews correlation coefficients (MCC) are reported. Numbers
in brackets correspond to 95% confidence intervals (95% C.I.) that
were obtained using bootstrap replicates (Robin et al., 2011).
(PDF)
Text S1 Text for supporting information.
(PDF)
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